Skip to main content
Premium Trial:

Request an Annual Quote

Six RNAi-Related Patent Applications Published by the USPTO: Aug 12, 2005

Premium

Title: Virally Encoded RNAs as Substrates, Inhibitors, and Delivery Vehicles for RNAi

Number: 20050171041

Filed: Aug. 23, 2004

Lead Inventor: Timothy Kowalik, University of Massachusetts

According to the patent application's abstract, the invention "provides methods for identifying druggable targets in assays that feature compositions, cells and/or organisms having structured viral non-coding RNAs (svRNAs) and an RNA interference pathway. Methods for identifying antiviral agents and creating vaccines are also featured. The invention further provides methods for inhibiting RNAi involving svRNAs or inhibitory derivatives thereof. The invention also provides compositions for delivering siRNA and miRNA molecules derived from svRNA loci and methods of use thereof. Therapeutic methods are also featured" in the application, the abstract notes.


Title: RNA Interference-Mediated Inhibition of Cholesteryl Ester Transfer Protein Gene Expression Using Short Interfering Nucleic Acid

Number: 20050171040

Filed: June 9, 2004

Lead Inventor: Barry Polisky, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of CETP genes."


Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050171039

Filed: May 11, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

The invention "concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity."


Title: Device and Method for Controlled Electroporation and Molecular Delivery into Cells and Tissues

Number: 20050170510

Filed: Dec. 7, 2004

Lead Inventor: Yong Huang, Excellin Life Sciences

According to the patent application's abstract, "in biology and biotechnology, electroporation is an important technique for introducing entities (DNA, RNAi, peptides, proteins, antibodies, genes, small molecules, nanoparticles, etc.) into cells. Applications range widely from genetic engineering to regenerative medicine to drug delivery. It has been demonstrated that the electrical currents flowing through cells can be used to monitor and control the process of electroporation for biological and artificial cells," the abstract notes. "In this application, a device and system are disclosed which allow precise monitoring and controlling electroporation of cells and cell layers, with examples shown using adherent cells grown on porous membranes."


Title: Expression Profiling Using Microarrays

Number: 20050170373

Filed: Sept. 10, 2004

Inventor: Joseph Monforte, Althea Technologies

"The invention provides novel compositions and methods for the analysis of gene expression (e.g., expression profiling) using microarray-based technology," the patent application's abstract states. "In some embodiments of the invention, the novel methods use gene-specific as well as universal amplification primers during sample preparation, and the methods permit the simultaneous analysis of multiple samples on the same microarray. Furthermore, some embodiments of the invention incorporate barcode sequences into the amplified products, thereby permitting the use of generic arrays and generic labeled probes."


Title: RNA Interference-Mediated Inhibition of 5-Alpha and Androgen Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050170371

Filed: Aug. 20, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention," the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating 5-alpha reductase (SRD5A-1, SRD5A-2) and androgen receptor gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of 5-alpha reductase and androgen receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of 5-alpha reductase and androgen receptor genes," the abstract adds.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.